Pancreatic Cancer Research

ResearcherSouth Texas Veterans Health Care SystemNo recent work listed

Michael B. Nicholl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8513-845X; OpenAlex author ID A5039830003. Sources: ClinicalTrials.gov.

Their work

Papers
2 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 2

  1. The Novel Use of IL-28 as an Effective Radiosensitizer in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16347↗
  2. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Last author DOI 10.1007/s12032-016-0880-3↗

Trials 1

  1. Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors Principal investigator NCT01412684↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yujiang Fang · 2 shared papers, 2017–2023 · strength 0.23
  2. Huaping Xiao · 1 shared paper, 2023 · strength 0.17
  3. Xuhui Chen · 1 shared paper, 2023 · strength 0.17
  4. Lei Zhao · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.